Which neurotransmitters, neuropeptides and receptor systems are implicated in schizophrenia?

Choice A reason: Schizophrenia involves a complex interplay of multiple neurochemical systems. While the dopamine hypothesis remains central, research extensively implicates serotonergic dysfunction, glutamatergic deficits (especially at NMDA receptors), and GABAergic imbalances. Additionally, the cholinergic system, involving both muscarinic and nicotinic receptors, is linked to the cognitive deficits and smoking prevalence seen in these patients. Choice B reason: While dopamine, serotonin, and glutamate are key, the omission of GABA and the cholinergic system makes this list incomplete. The endocannabinoid system has been studied regarding the relationship between cannabis use and psychosis, but the specific receptor systems in Choice A are more comprehensively established in the core pathophysiology and pharmacological treatment of schizophrenia. Choice C reason: This choice correctly identifies glutamate, serotonin, and GABA, but excludes dopamine, which is the most critical neurotransmitter in the development of positive psychotic symptoms. Furthermore, nitric acid is not a standard neurotransmitter or neuropeptide implicated in the primary diagnostic neurobiology of schizophrenia compared to the nicotinic system. Choice D reason: Although this list includes many relevant substances, Choice A provides a more precise clinical mapping of the systems targeted by contemporary antipsychotics and those identified in neurodevelopmental models. The inclusion of muscarinic and nicotinic receptors is vital because they are critical targets for emerging medications focusing on cognitive enhancement in schizophrenia.